NO339699B1 - Krystallinsk form av en quinolinonkarboksamidforbindelse - Google Patents

Krystallinsk form av en quinolinonkarboksamidforbindelse Download PDF

Info

Publication number
NO339699B1
NO339699B1 NO20075574A NO20075574A NO339699B1 NO 339699 B1 NO339699 B1 NO 339699B1 NO 20075574 A NO20075574 A NO 20075574A NO 20075574 A NO20075574 A NO 20075574A NO 339699 B1 NO339699 B1 NO 339699B1
Authority
NO
Norway
Prior art keywords
salt form
crystalline salt
crystalline
form according
oxo
Prior art date
Application number
NO20075574A
Other languages
English (en)
Norwegian (no)
Other versions
NO20075574L (no
Inventor
Paul Ross Fatheree
Daniel Genov
Robert S Chao
Adam A Goldblum
S Derek Turner
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of NO20075574L publication Critical patent/NO20075574L/no
Publication of NO339699B1 publication Critical patent/NO339699B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20075574A 2005-04-06 2007-11-02 Krystallinsk form av en quinolinonkarboksamidforbindelse NO339699B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66878005P 2005-04-06 2005-04-06
PCT/US2006/012978 WO2006108127A2 (en) 2005-04-06 2006-04-05 Crystalline form of a quinolinone-carboxamide compound

Publications (2)

Publication Number Publication Date
NO20075574L NO20075574L (no) 2007-11-02
NO339699B1 true NO339699B1 (no) 2017-01-23

Family

ID=37074104

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075574A NO339699B1 (no) 2005-04-06 2007-11-02 Krystallinsk form av en quinolinonkarboksamidforbindelse

Country Status (29)

Country Link
US (4) US7728004B2 (cg-RX-API-DMAC7.html)
EP (1) EP1874766B1 (cg-RX-API-DMAC7.html)
JP (2) JP5230407B2 (cg-RX-API-DMAC7.html)
KR (1) KR101322873B1 (cg-RX-API-DMAC7.html)
CN (1) CN101151264B (cg-RX-API-DMAC7.html)
AR (2) AR053208A1 (cg-RX-API-DMAC7.html)
AT (1) ATE479682T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006232129B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0610657A2 (cg-RX-API-DMAC7.html)
CA (1) CA2603654C (cg-RX-API-DMAC7.html)
CY (1) CY1111275T1 (cg-RX-API-DMAC7.html)
DE (1) DE602006016586D1 (cg-RX-API-DMAC7.html)
DK (1) DK1874766T3 (cg-RX-API-DMAC7.html)
EA (1) EA012115B1 (cg-RX-API-DMAC7.html)
ES (1) ES2350495T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20100629T1 (cg-RX-API-DMAC7.html)
IL (1) IL186023A (cg-RX-API-DMAC7.html)
MA (1) MA29403B1 (cg-RX-API-DMAC7.html)
MX (1) MX2007012438A (cg-RX-API-DMAC7.html)
MY (1) MY151075A (cg-RX-API-DMAC7.html)
NO (1) NO339699B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ561900A (cg-RX-API-DMAC7.html)
PE (1) PE20061310A1 (cg-RX-API-DMAC7.html)
PL (1) PL1874766T3 (cg-RX-API-DMAC7.html)
PT (1) PT1874766E (cg-RX-API-DMAC7.html)
SI (1) SI1874766T1 (cg-RX-API-DMAC7.html)
TW (1) TWI377206B (cg-RX-API-DMAC7.html)
WO (1) WO2006108127A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200708071B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063671B2 (en) * 2002-06-21 2006-06-20 Boston Scientific Scimed, Inc. Electronically activated capture device
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
ES2332808T3 (es) * 2004-11-05 2010-02-12 Theravance, Inc. Compuestos agonistas del receptor 5-ht4.
US7396933B2 (en) 2004-11-05 2008-07-08 Theravance, Inc. Quinolinone-carboxamide compounds
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
SI1945632T1 (sl) 2005-11-08 2014-03-31 Vertex Pharmaceuticals Incorporated Heterocikliäśni modulatorji za prenaĺ alce z atp-vezavno kaseto
JP2010527357A (ja) * 2007-05-17 2010-08-12 セラヴァンス， インコーポレーテッド 腸の前処置のための運動促進剤
CH698729B1 (de) * 2007-05-30 2009-10-15 Cerbios Pharma Sa Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure.
PT2225230T (pt) * 2007-12-07 2016-12-07 Vertex Pharma Formas sólidas de ácido 3-(6(1-(2,2-difluorobenzo[d][1,3] dioxol-5-il) ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
LT2419104T (lt) 2009-04-13 2018-02-12 Theravance Biopharma R&D Ip, Llc 5-ht4 receptoriaus agonistų ir acetilcholinesterazės inhibitorių deriniai, skirti pažinimo sutrikimų gydymui
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
US8835444B2 (en) 2010-02-02 2014-09-16 Novartis Ag Cyclohexyl amide derivatives as CRF receptor antagonists
HRP20211752T1 (hr) 2010-04-07 2022-02-18 Vertex Pharmaceuticals Incorporated Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
KR102280372B1 (ko) 2013-11-12 2021-07-22 버텍스 파마슈티칼스 인코포레이티드 Cftr 매개된 질환 치료용 약제학적 조성물의 제조 방법
SG11201912266QA (en) * 2017-07-31 2020-01-30 Theravance Biopharma R&D Ip Llc Methods of treating symptoms of gastroparesis using velusetrag
US10570127B1 (en) 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders
WO2024061960A1 (en) 2022-09-20 2024-03-28 Alfasigma S.P.A. Velusetrag for use in the treatment of chronic intestinal pseudo-obstruction (cipo)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564650A1 (en) * 1990-12-28 1993-10-13 Kyowa Hakko Kogyo Co., Ltd. Quinoline derivative
WO2005100350A1 (en) * 2004-04-07 2005-10-27 Theravance, Inc. Quinolinone-carboxamide compounds as 5-ht4 receptor agonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3122671B2 (ja) * 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
US5571820A (en) * 1992-11-20 1996-11-05 Taisho Pharmaceutical Co., Ltd. Heterocyclic compound
JP3829879B2 (ja) * 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
TW402591B (en) * 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US7105195B2 (en) * 2003-07-25 2006-09-12 General Mills, Inc. Reduced trans fat product
ES2338882T3 (es) 2003-11-24 2010-05-13 Pfizer, Inc. Compuestos de acido quinolona-carboxilico que tienen actividad agonista del receptor 5-ht4.
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US7396933B2 (en) * 2004-11-05 2008-07-08 Theravance, Inc. Quinolinone-carboxamide compounds
ES2332808T3 (es) * 2004-11-05 2010-02-12 Theravance, Inc. Compuestos agonistas del receptor 5-ht4.
WO2006088988A1 (en) 2005-02-17 2006-08-24 Theravance, Inc. Crystalline form of an indazole-carboxamide compound
BRPI0608392A2 (pt) * 2005-03-02 2009-12-29 Theravance Inc compostos de quinolinona como agonistas do receptor 5-ht4
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564650A1 (en) * 1990-12-28 1993-10-13 Kyowa Hakko Kogyo Co., Ltd. Quinoline derivative
WO2005100350A1 (en) * 2004-04-07 2005-10-27 Theravance, Inc. Quinolinone-carboxamide compounds as 5-ht4 receptor agonists

Also Published As

Publication number Publication date
EA200702161A1 (ru) 2008-04-28
KR101322873B1 (ko) 2013-10-30
DK1874766T3 (da) 2010-12-06
EP1874766B1 (en) 2010-09-01
US20100197728A1 (en) 2010-08-05
NO20075574L (no) 2007-11-02
WO2006108127A3 (en) 2007-01-04
US20140256769A1 (en) 2014-09-11
MY151075A (en) 2014-03-31
JP2012153725A (ja) 2012-08-16
US9126994B2 (en) 2015-09-08
US7728004B2 (en) 2010-06-01
WO2006108127A2 (en) 2006-10-12
CN101151264A (zh) 2008-03-26
SI1874766T1 (sl) 2010-12-31
IL186023A0 (en) 2008-01-20
TWI377206B (en) 2012-11-21
CA2603654A1 (en) 2006-10-12
US8658671B2 (en) 2014-02-25
US9402840B2 (en) 2016-08-02
TW200643020A (en) 2006-12-16
CY1111275T1 (el) 2015-08-05
PE20061310A1 (es) 2007-01-23
PT1874766E (pt) 2010-11-30
DE602006016586D1 (de) 2010-10-14
JP2008535848A (ja) 2008-09-04
MA29403B1 (fr) 2008-04-01
CA2603654C (en) 2014-05-27
MX2007012438A (es) 2007-12-05
IL186023A (en) 2011-09-27
AR053208A1 (es) 2007-04-25
HK1110866A1 (en) 2008-07-25
KR20070116988A (ko) 2007-12-11
EP1874766A2 (en) 2008-01-09
EA012115B1 (ru) 2009-08-28
ES2350495T3 (es) 2011-01-24
JP5230407B2 (ja) 2013-07-10
ATE479682T1 (de) 2010-09-15
US20160095849A1 (en) 2016-04-07
AU2006232129B2 (en) 2012-07-12
PL1874766T3 (pl) 2011-02-28
ZA200708071B (en) 2008-10-29
NZ561900A (en) 2010-12-24
HRP20100629T1 (hr) 2010-12-31
AU2006232129A1 (en) 2006-10-12
US20060229332A1 (en) 2006-10-12
AR110019A2 (es) 2019-02-13
CN101151264B (zh) 2011-07-06
BRPI0610657A2 (pt) 2010-07-13

Similar Documents

Publication Publication Date Title
NO339699B1 (no) Krystallinsk form av en quinolinonkarboksamidforbindelse
CA2561558C (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
WO2005080389A1 (en) Indazole-carboxamide compounds as 5-ht4 receptor agonists
EP1807423B1 (en) Quinolinone-carboxamide compounds
WO2006052640A1 (en) 5-ht4 receptor agonist compounds
US8288550B2 (en) Crystalline form of a benzimidazole-carboxamide medicinal compound
EP1871772B1 (en) Quinolinone compounds as 5-ht4 receptor agonists
US20060183901A1 (en) Crystalline form of an indazole-carboxamide compound
EP1960396A2 (en) Carbamate compounds as 5-ht4 receptor agonists
HK1110866B (en) Crystalline form of a quinolinone-carboxamide compound
MXPA06009176A (en) Indazole-carboxamide compounds as 5-ht4 receptor agonists

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: THERAVANCE BIOPHARMA R&D IP, US

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: THERAVANCE BIOPHARMA R&D IP, US

MM1K Lapsed by not paying the annual fees